^
Association details:
| Biomarker: | TPM3-NTRK1 fusion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
Published date:
02/24/2021
Excerpt:
TPM3-NTRK1 fusion gene-positive KM12 colorectal cancer cells were highly sensitive to gilteritinib...
DOI:
https://doi.org/10.1038/s41467-021-21396-w
